![]() |
|
|
Vol. 294, Issue 2, 466-472, August 2000
2-Adrenergic Receptors Stimulate
Oligopeptide Transport in a Human Intestinal Cell Line1
Institut National de la Santé et de la Recherche Médicale, Faculté X. Bichat, Paris (F.B., J.-J.M., M.L., C.R.); Institut National de la Santé et de la Recherche Médicale, Institut Louis Bugnard, Toulouse (H.P.); and Unité Propre de Recherches de I'Enseignement Supérieure, Faculté de Pharmacie, Chatenay-Malabry, France (F.B., R.F.)
| |
Abstract |
|---|
|
|
|---|
Di- and tripeptides, as well as peptidomimetic drugs such as cephalexin
(CFX), are absorbed by enterocytes via the oligopeptide transporter
PepT1. We recently showed that the
2-adrenergic agonist clonidine increases CFX absorption in anaesthetized rats. Herein, we
investigated whether
2-adrenergic receptors can directly
affect PepT1 activity in a clone of the differentiated human intestinal cell line Caco-2 (Caco-2 3B) engineered to stably express
2A-adrenergic receptors at a density similar to that
found in normal mucosa. Measurement of CFX fluxes across cell
monolayers cultured on transwell filters demonstrated that the
2-agonists clonidine and UK14304 caused a 2-fold
increase of CFX transport in Caco-2 3B cells, but not in Caco-2
(expressing PepT1 but not
2-adrenergic receptors) or in
the HT29 19A clone (expressing
2-adrenergic receptors
but not PepT1). The stimulatory effect of clonidine was abolished by
glycyl-sarcosine (a competitor for the transporter) and blocked by
yohimbine or RX821002 (
2-antagonists). Analysis of the
kinetics of CFX transport in control and clonidine-treated Caco-2 3B
cells showed that clonidine increased Vmax
of CFX transport without changing Km.
Clonidine action was abolished by colchicine but not altered by
amiloride, demonstrating that microtubule integrity but not
Na+/H+ exchanger activity is necessary for the
effect of
2-agonists to occur. In conclusion, clonidine
can directly activate
2-adrenergic receptors located on
epithelial cells. The precise molecular mechanisms whereby these
receptors modulate PepT1 activity remain to be elucidated but an
increased translocation to the apical membrane of preformed cytoplasmic
transporter molecules is likely to be involved.
| |
Introduction |
|---|
|
|
|---|
The
H+/oligopeptide cotransporter PepT1 is a 12 transmembrane domain protein located in the brush-border membrane of
enterocytes that is specific for di- and tripeptides arising from
digestion of dietary proteins (for review, see Leibach and Ganapathy,
1996
). Besides its key role in nutrient absorption, PepT1 is also
pharmacologically relevant because its activity is responsible for
absorption of peptidomimetic drugs such as
-lactam antibiotics.
Although several studies have been carried out on the functional and
molecular characteristics of PepT1 (Liang et al., 1995
; Mackenzie et
al., 1996
), little information is available on the regulation of its
activity (Brandsch et al., 1994
; Muller et al., 1996
; Fujita et al.,
1997
, 1999
; Thamotharan et al., 1999b
). A recent study demonstrated
transcriptional enhancement of PepT1 expression in rats fed with
protein-rich diet. However, in a previous work with a single-pass
jejunal perfusion technique in anaesthetized rats, we showed that
intestinal absorption of the
-lactam antibiotic cephalexin (CFX),
which is carried by PepT1, was influenced by the nervous system
(Berlioz et al., 1999
). In our experiments, stimulation of PepT1
occurred very rapidly, excluding a transcriptional control, and
depended on the activity of intramural and/or extramural neuron
networks, including nicotinic synapses, intestinal sensory neurons, and
sympathetic noradrenergic fibers. Among the agents acting on
neurotransmitter receptors that were tested, administration of the
2-agonist clonidine induced a 2-fold increase of the
intestinal absorption of CFX. In the small intestine,
2-adrenergic receptors are present on enteric neurons,
on extrinsic sympathetic postganglionic neurons (Cooke and Reddix,
1994
), and also on intestinal epithelial cells (Laburthe et al., 1982
;
Nakaki et al., 1983
). Thus, the precise location of the receptor
responsible for the stimulatory effect of clonidine in vivo is unclear.
The purpose of this study was to investigate whether
2-adrenergic receptors can directly affect the transport
of peptidomimetic drugs in cultured epithelial cells devoid of innervation.
To fulfill this objective, we needed to use a polarized intestinal cell
line possessing PepT1 and
2-adrenergic receptors. However, a cell model spontaneously expressing both proteins is not
currently available. The HT29 colonic cells express
2-adrenergic receptors but not PepT1 (Langin et al.,
1989
, 1995). Conversely, Caco-2 cells, frequently used to study
intestinal drug absorption (Zweibaum et al., 1991
) show enterocytic
differentiation and express the PepT1 transporter (Liang et al., 1995
)
but not the
2-adrenergic receptor (Devedjian et al.,
1991
). The absence of suitable model was recently circumvented by the
generation of a clone of Caco-2 cells stably transfected with the
2C10 adrenergic receptor gene. This clone, referred to
as Caco-2 3B (Schaak et al., 2000
), expresses
2-adrenergic receptors at a density similar to that
found on enterocytes and colonocytes of different species, including
humans (Paris et al., 1990
; Senard et al., 1990
; Valet et al., 1993
). As in normal intestinal cells, the receptor is coupled to
Gi2 and Gi3 and its
stimulation inhibits forskolin-stimulated cAMP production. We thus
decided to use Caco-2 3B cells to study a possible direct involvement
of
2-adrenergic receptors in the activation of CFX transport.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Caco-2 cells were purchased from the American
Type Culture Collection (Rockville, MD). HT-29 clone 19A cells were a
generous gift from C. Laboisse (CJF 9404, Nantes, France). The clone of Caco-2 cells (Caco-2 3B) expressing
2-adrenergic
receptors was obtained by transfection of the parental cell-line with
the bicistronic plasmid p
2C10ENeo containing the coding
region of the human
2A-adrenergic receptor subtype
(Schaak et al., 1999
). Dulbecco's modified Eagle's medium (DMEM),
trypsin solution, and fetal calf serum (FCS) were purchased from
Gibco-BRL (Cergy Pontoise, France). Cephalexin, clonidine, yohimbine,
glycyl-sarcosine, amiloride, and colchicine were obtained from Sigma
(St. Louis, MO). UK14304 and RX821002 were donated by Pfizer (Sandwich,
UK) and Reckitt and Colman Laboratories (Kingston-upon-Hull, UK),
respectively. [14C]Mannitol (specific
radioactivity, 57 Ci/mmol) and [3H]RX821002
(specific radioactivity, 53 Ci/mmol) were purchased from Amersham
(Amersham, UK). [3H]Clonidine (specific
radioactivity, 66 mCi/mmol) was from New England Nuclear (Boston, MA).
Cell Culture.
Caco-2 3B (passages 18-27) and Caco-2
(passages 35-37) cells were propagated in 25-cm2
flasks at 37°C in a humidified 5% CO2
incubator in DMEM supplemented with 20% FCS and 1% nonessential amino
acids (Zweibaum et al., 1991
). When reaching confluency, cells were
trypsinized and plated (starting density, 5 × 104 cells/cm2) on Transwell
Clear polyester membranes, 1 cm2 in surface and
0.4 µm in pore size (Costar, Dutscher, France). Culture medium was
changed every day and, except where noted, monolayers at day 16 to 17 postseeding were used for transport experiments. HT-29 clone 19A cells
(passage 154) were subcultured and plated as Caco-2, except they were
grown in DMEM supplemented with 10% FCS and 1% nonessential amino acids.
Adrenergic Receptor Quantification.
The expression of
2-adrenergic receptors in the different cell types was
assessed by binding studies with [3H]RX821002
(
2-antagonist) and [3H]clonidine
(
2-agonist) as specific radioligands. Binding
experiments were performed on crude membranes prepared from frozen
cells as described previously (Paris et al., 1990
). Briefly, total
binding was measured by incubating 100 µl of membranes with the
radioligand in a total volume of 400 µl of binding buffer (50 mM
Tris-HCl, 0.5 mM MgCl2, pH 7.5). After a 45-min
incubation at 25°C, bound radioactivity was separated from free by
filtration through GF/C Whatman filters with a Millipore manifold
sampling unit. Filters were rapidly washed with ice-cold buffer and
bound radioactivity was determined by liquid spectrometry. Specific
binding was defined as the difference between total and nonspecific
binding measured as described above but in the presence of 10 µM
phentolamine. Final concentrations of radioligand ranged from 0.1 to 10 nM for [3H]RX821002 and from 0.05 to 8 nM for
[3H]clonidine. Saturation isotherms were
analyzed with the EBDA-LIGAND computer programs (McPherson, 1985
) and
protein concentration was determined with the Coomassie blue method
(Bradford, 1976
).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR).
Total RNAs were extracted from Caco-2, Caco-2 3B, and HT-29 19A cells
with RNAXEL (Eurobio, Les Ulis, France) according to the
manufacturer's instructions. Ten micrograms of total RNA was reverse
transcribed with Moloney murine leukemia virus RNase at 37°C
for 45 min and then heated at 80°C for 5 min. The synthesized cDNA
was used for subsequent PCR with two sets of primers allowing us to
amplify either PepT1 or GAPDH, taken as a control for housekeeping gene. The primers for PepT1 were identical with those used in Liang et
al. (1995)
. The sense 5'-TCCACCGCCATCTACCATAC-3' and antisense
5'-GGACAAACACAATCAGGGCT-3' primers allow amplification of a 479-base
pair fragment corresponding to nucleotides 210 to 708 of the human
PepT1 cDNA. Primers for GADPH were as follows: 5'-TGAAGGTCGGAGTCAACGGATTTGGT-3' (sense) and
5'CATGTGGGCCATGAGGTCCACCAC-3' (antisense). Reaction mixtures were
subjected to 35 cycles consisting of 30 s at 92°C, 30 s at
58°C, and 1 min at 72°C. The PCR products were electrophoresed on a
1% agarose gel and stained with ethidium bromide.
Transport Studies.
The day of the experiment, the
transepithelial resistance of each cell layer was measured with a
Millicel-ERS ohmmeter (Millipore, St. Quentin en Yvelines,
France). Monolayers exhibiting a transepithelial resistance
above 150
/cm2 were considered as satisfactory
and were further used for the transport experiments. Before transport
studies, the culture medium was removed and the apical and basolateral
compartments were washed three times with Krebs' solutions [137 mM
NaCl, 5.4 mM KCl, 2.8 mM CaCl2, 1 mM
MgSO4, 0.3 mM NaHPO4, 0.3 mM KH2PO4) buffered with either 10 mM HEPES/Tris, pH 7.4 (basolateral compartment) or 10 mM
Mes/Tris, pH 6.0 (apical compartment)]. Cell monolayers were incubated
for 15 min at 37°C under continuous circular shaking in Krebs'
modified buffer (pH 6.0 in the apical compartment and 7.4 in the
basolateral compartment). Unless otherwise specified, at zero time of
the experiment, CFX (final concentration 1 mM) was added to the apical
compartment. The rate of CFX transport was estimated over a 30 min-period by measuring CFX concentration (see below) in 50-µl
aliquots taken from the basolateral compartment every 5 min. For
competition experiments, glycyl-sarcosine (50 mM) was added to the
apical compartment before the addition of CFX. The
2-adrenergic drugs (clonidine, UK14304, yohimbine, or RX821002) were added to the basolateral compartment 15 min after CFX.
The effects of these pharmacological agents were evaluated on the same
cell monolayer by comparing basal CFX flux (calculated from the three
samples taken during the 0- to 15-min incubation period) with the flux
measured after their addition (calculated from the three samples taken
during the 15- to 30-min incubation period). In some experiments, cells
were pretreated with colchicine (20 µM) or amiloride (10 µM); these
inhibitors were added to the apical compartment 25 and 10 min,
respectively, before the addition of CFX.
Determination of CFX Concentration. CFX concentration was measured by HPLC on a Supelcosil LC18 column (250 × 4.6 mm, 5-µm particle size; Supelco, Touzart et Matignon, France). The HPLC apparatus comprised a WISP 712 automatic sampler (Waters, Paris, France), an SPD-6AV pump, and an SPD-6AV UV detector (Shimadzu, Paris, France) set at 260 nm to monitor the CFX peak that came off at 14 min. The mobile phase was a mixture of sodium acetate buffer (0.01 M, pH 5.2) and acetonitrile (94.5:4.5, v/v). The flow rate was 1.5 ml/min.
Data Analysis. The experiments were performed in triplicate and repeated twice. The data are presented as mean ± S.E.M. The means were compared by paired or unpaired Student's t test, as appropriate; P < .05 was considered significant. The kinetic constants of CFX transport were determined by applying a nonlinear regression method to fit the Michaelis-Menten kinetic equation with the GRAFIT program. Vmax is the maximal CFX flux and Km is the concentration of CFX that yielded one-half of Vmax. To determine the number of systems involved in CFX transport, the CFX fluxes were transformed according to the Eadie-Hofstee method, by plotting V against V/S were V is the CFX flux in nanograms per square centimeter per minute and S the apical CFX concentration in millimolar.
| |
Results |
|---|
|
|
|---|
Junctional Integrity and Expression of hPepT1 in Caco-2 3B Cell
Line.
Caco-2 is a human colon cancer cell line that has retained
the remarkable property to spontaneously differentiate and to behave as
a functional epithelium. Thus, this cell line has been extensively used
as a model to study transepithelial transport of a large panel of
molecules, including dipeptides. Emergence of the differentiated phenotype is growth-related and it can be monitored by measuring changes in transepithelial electrical resistance (TEER) and in paracellular diffusion, which both reflect appearance of tight junctions. The Caco-2 3B clone was recently generated by stable transfection and this model was never used before for transport study.
Preliminary experiments were therefore designed to assess its
epithelial properties. TEER and [14C]mannitol
flux were measured in Caco-2 3B monolayers from day 3 to day 24 postseeding. During the time interval between days 3 and 15, TEER
increased 4-fold from 45 ± 6 to 180 ± 5
/cm2. Conversely, the percentage of passive
diffusion of mannitol decreased 17-fold from 0.50 ± 0.02 to
0.030 ± 0.002%/cm2/min. The two parameters
remained stable between days 15 and 24. All further experiments were
carried out on monolayers at days 16 to 17 postseeding.
2-adrenergic receptors was estimated by radioligand
binding (Fig. 1C). Analysis of [3H]RX821002
saturation isotherms confirmed that Caco-2 cells do not express this
receptor. It also indicated that receptor density was 119 ± 14 fmol/mg of protein in Caco-2 3B (n = 12) and 158 ± 11 fmol/mg of protein in HT29 clone 19A (n = 3).
Moreover, according to [3H]clonidine binding,
60 to 70% of the receptor population was under high-affinity state for
agonists, indicative of efficient coupling to G-protein.
|
Effect of
2-Adrenergic Receptor Stimulation on CFX
Absorption.
To investigate whether activation of
2-adrenergic receptors had any effect on CFX transport,
clonidine was added to the basolateral compartment, 15 min after adding
CFX to the apical compartment. As depicted in the Fig.
2, addition of the
2-agonist caused a rapid increase of the flux of CFX
through the Caco-2 3B monolayer. Calculation of the slope of the
absolute values of CFX fluxes against time under basal and stimulated
conditions (Fig. 2) revealed a doubling of the mean rate of CFX
transport from 5.9 ± 0.5 to 12.0 ± 0.6 ng/cm2 · min. The stimulatory effect of
clonidine was not observed in the presence of glycyl-sarcosine,
indicating that it reflects an increase of PepT1 activity (Fig.
3). The effect of clonidine was mimicked
by UK14304 (Fig. 3). However, the effects of the two
2-agonists were totally blocked by two specific
2-antagonists with different chemical structures,
yohimbine and RX821002, strongly suggesting the involvement of
2-adrenergic receptors in the observed effect (Fig. 3).
|
|
2-adrenergic receptor and subsequent activation of
PepT1 was further confirmed by the study of the effect of this
2-agonist on Caco-2 and HT29 19A monolayers. Indeed,
clonidine failed to activate CFX transport in these two models, which
lack either
2-adrenergic receptor or PepT1 (Caco-2,
7.8 ± 0.6 versus 8.4 ± 0.6 ng/cm2 · min; HT29 19A, 0.30 ± 0.01 versus 0.32 ± 0.01 µg/cm2/min), respectively.
Mechanism of PepT1 Stimulation.
The stimulation of CFX uptake
caused by the
2-agonist may be the consequence of an
increase in the affinity of the oligopeptide transporter for its
substrate, and/or of an augmentation of the number of transporter
molecules functionally available at the apical membrane of Caco-2 3B
cells. The effect of clonidine on the kinetics of CFX transport was
thus investigated to clarify this point. The transformation of the
kinetic data yielded linear Eadie-Hofstee plots (Fig.
4), indicating the presence of a single class of transporters in both control and clonidine-treated cells. Furthermore, the treatment with the
2-agonist resulted
in a significant (P < .05) increase of the
Vmax value from 54.4 ± 9.1 to
92.8 ± 13.4 ng/cm2 · min without any
modification of the Km value
(2.64 ± 0.79 versus 2.78 ± 0.69 mM). These data indicate
that another transporter system is not recruited after
2-agonist exposure. They also eliminate the possibility
that a change in the intrinsic properties of the oligopeptide
transporter occurred.
|
2-adrenergic receptor
stimulation by clonidine provokes a raise in the intracellular pH of
enterocytes by increasing the
Na+/H+ exchanger activity
(Sundaram, 1995
|
2-agonist effect is an increase of the membranous
population of hPepT1 by translocation from a preformed cytoplasmic
pool. Such a mechanism was already demonstrated for the effect of
insulin on hPepT1 in Caco-2 cells (Thamotharan et al., 1999b| |
Discussion |
|---|
|
|
|---|
Previous experiments conducted in anaesthetized rats have
demonstrated that administration of clonidine resulted in a rapid enhancement of intestinal absorption of CFX through increased activity
of the oligopeptide transporter PepT1. This effect might either be the
consequence of the stimulation of
2-adrenergic receptors
located on neurons from the central nervous system, sympathetic system,
or intramural network or be due to the direct activation of
2-adrenergic receptors located on enterocytes. A clone
of Caco-2 stably expressing
2-adrenergic receptors
(Caco-2 3B; Schaak et al., 2000
) was therefore used as a model to
determine whether
2-agonists can directly modulate the
activity of the dipeptide carrier PepT1 in the absence of nerve endings.
Preliminary experiments were designed to verify that the transfection
and the selection of the Caco-2 3B clone had no incidence on epithelial
properties and PepT1 expression. The measurement of TEER and the
estimation of mannitol diffusion demonstrated that tightness of Caco-2
3B monolayers was identical with that of the parental cell line. The
expression of PepT1 was assessed by RT-PCR and the functionality of the
oligopeptide transporter was evidenced by the large inhibition of CFX
transport by glycyl-sarcosine. Finally, the
Km of PepT1 for CFX in Caco-2 3B
(2.64 ± 0.79 mM) was fairly similar to that previously reported
in Caco-2 cells (Gochoco et al., 1994
).
Exposure of Caco-2 3B cells to clonidine resulted in a doubling of CFX
transport. The involvement of
2-adrenergic receptors in
this response is obvious because the effect of clonidine was mimicked
by UK14304 (another
2-agonist), blocked by RX821002 or
yohimbine (
2-antagonists), and absent in Caco-2 cells,
which express PepT1 but not the receptor. However, the implication of PepT1 is proved because the clonidine-induced increase of CFX transport
was abolished in the presence of an excess of glycyl-sarcosine and was
not observed in HT29 clone 19A, which expresses the
2-receptor but not PepT1.
Changes in PepT1 activity have been reported in the rat intestine as a
consequence of starvation (Ogihara et al., 1999
; Thamotharan et al.,
1999a
), dietary protein content (Erickson et al., 1995
; Shiraga et al.,
1999
), or epithelium injury by 5-fluorouracil (Tanaka et al., 1998
). In
Caco-2, an augmentation in the amount of PepT1 also was found after
complementation of the culture medium with glycyl-glutamine (Walker et
al., 1998
) and after cell exposure to pentazocine, a selective ligand
of
-receptor (Fujita et al., 1999
). In all these cases,
up-regulation of PepT1 correlated with increased level of its mRNA.
Although mRNA levels were not examined in this study, a modification of
PepT1 gene expression is unlikely because the increase of CFX transport
occurred within minutes after exposure to the
2-agonist.
Clonidine also was previously shown as able to raise the intracellular
pH of intestinal epithelial cells by increasing the activity of the
Na+/H+ exchanger (Sundaram,
1995
). An alkalinization of the intracellular compartment might
indirectly affect CFX flux because oligopeptide transport is
electrogenic and PepT1 activity is highly dependent on the
H+-gradient (Fei et al., 1994
; Mackenzie et al.,
1996
). In our experiments, amiloride, however, did not alter the extent
of clonidine effect, suggesting that the
Na+/H+ exchanger is not involved.
The determination of PepT1 kinetic parameters showed that the
stimulation of CFX flux by clonidine solely resulted from an increase
in the population of functionally active PepT1 (increase in
Vmax but no change in
Km). Furthermore, this effect was
abolished after microtubule disruption by colchicine. It is thus
possible that
2-agonists act by increasing the insertion
of transporter molecules, recruited from a preformed cytoplasmic pool,
into the apical membrane of Caco-2 3B. A similar mechanism of
translocation was demonstrated to account for the effect of insulin on
PepT1 activity in Caco-2 cells (Thamotharan et al., 1999b
). Further study with anti-PepT1 antibody on brush-border membrane purified from
Caco-2 3B is necessary to verify this hypothesis.
The intracellular messenger responsible for the redistribution of PepT1
molecules was not determined in this study. cAMP and protein kinase C
may appear as possible candidates. Indeed, a previous study with Caco-2
has shown that elevation of cAMP levels induced by cholera toxin or
heat-labile enterotoxin inhibits PepT1 activity (Muller et al., 1996
).
Because PepT1 is devoid of site for phosphorylation by protein kinase A
but does possess two putative sites for phoshorylation by protein
kinase C, and because phorbol esters inhibit the transporter activity
(Brandsch et al., 1994
), it is thought that the effect of cAMP may be
indirectly mediated by protein kinase C (Muller et al., 1996
). With the
2-adrenergic receptor being negatively coupled to
adenylate cyclase (Remaury et al., 1993
), one could expect that
decreased intracellular level of cAMP may conversely result in enhanced
PepT1 activity. However, two arguments make such a mechanism of action
unlikely. First, regardless the cellular system examined,
2-agonists were never found to inhibit protein kinase C. Second, if clonidine and other
2-agonists are able to
inhibit forskolin-induced cAMP production in Caco-2 3B cells (Schaak et
al., 2000
), they are unable to lower the level of this intracellular
messenger in basal conditions such as those under which the effects on
PepT1 activity are observed. In contrast,
2-agonists per
se were found to activate mitogen-activated protein kinase in
Caco-2 3B via a cascade of events comprising recruitment of
Gi-proteins, G
-subunit-mediated formation of Shc-Grb2-SOS
complex, and subsequent activation of mitogen-activated protein kinase
kinase 1. Furthermore, stimulation of
2-adrenergic receptors was proved to evoke focal
adhesion kinase phosphorylation and a rapid rearrangement of
actin cytoskeleton in smooth muscle cells (Richman and Regan, 1998
) and
preadipocytes (Betuing et al., 1996
). In this latter case, the effect
of
2-agonists was correlated with stimulation of RhoA
via a G
-subunit-independent mechanism. Activation of the
RhoA/focal adhesion kinase pathway was not demonstrated yet in Caco-2
3B, but the possibility exists that the effect of
2-agonists on PepT1 is triggered by one of these two
cAMP-independent mechanisms. In support to this view, it is worth
mentioning that substantial amounts of Gi-proteins were found
intracellularly in Caco-2 (Lacombe et al., 1996
) and that these
proteins were demonstrated to regulate trafficking of a number of
transporters, including cystic fibrosis transmembrane conductance
regulator (Schwiebert et al., 1994
) and aquaporin (Valenti et
al., 1998
).
Finally, another point that needs to be addressed is whether our
results obtained on a cell line can be extrapolated to the in vivo
situation. Indeed, previous studies have shown that
2-adrenergic receptors are abundant in crypt cells,
whereas they are scarce in villus cells (Paris et al., 1990
; Valet et
al., 1993
). Conversely, PepT1 amount is high in villus cells but low in
crypt cells (Ogihara et al., 1996
). It is therefore questionable
whether the density of receptors in villus cells is sufficient to
affect PepT1 function. The measurement of CFX transport on cells
isolated from the villi is presently impossible; but experiments on
other clones of Caco-2 expressing a lower amount of receptor may
provide an answer to this issue. It is however noteworthy that the
density of
2-adrenergic receptors in the villi is high
enough to stimulate activity of the
Na+/H+ exchanger (Sundaram,
1995
). One could hypothesize that the same is true for PepT1.
In conclusion, our data demonstrate that activation of an epithelial
Gi-protein-coupled neurotransmitter receptor can increase the
intestinal absorption of peptides and peptidomimetic drugs. Although
the mechanisms involved in this effect remain to be elucidated and the
relative participation of epithelial and neural receptors remains to be
precisely delineated in vivo, the amplitude of the
2-agonist effect is sufficient to be of interest to
peptidomimetic drugs poorly absorbed by the intestine and to
potentially represent a new field for therapeutic application of
2-agonists.
| |
Footnotes |
|---|
Accepted for publication April 7, 2000.
Received for publication February 10, 2000.
1 This study was funded in part by Institut de Recherches sur les Maladies de l'Appareil Digestif and by Association Charles Debray. F.B. was the recipient of a grant from the Fondation pour la Recherche Médicale.
Send reprint requests to: Dr. C. Rozé, Institut National de la Santé et de la Recherche Médicale U410, Faculté de Médecine X. Bichat, 16 rue H. Huchard, 75018 Paris, France. E-mail: roze{at}bichat.inserm.fr
| |
Abbreviations |
|---|
PepT1, H+/peptide cotransporter; CFX, cephalexin; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; UK14304, 5-bromo-6-(2-imidazoline-2-ylamino)-quinoxaline; RX821002, 2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline; RT-PCR, reverse transcription-polymerase chain reaction; TEER, transepithelial electrical resistance.
| |
References |
|---|
|
|
|---|
channels.
Am J Physiol
267:
C272-C281This article has been cited by other articles:
![]() |
P. Hindlet, A. Bado, R. Farinotti, and M. Buyse Long-Term Effect of Leptin on H+-Coupled Peptide Cotransporter 1 Activity and Expression in Vivo: Evidence in Leptin-Deficient Mice J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 192 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shimakura, T. Terada, H. Saito, T. Katsura, and K.-i. Inui Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor {alpha} Am J Physiol Gastrointest Liver Physiol, November 1, 2006; 291(5): G851 - G856. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shimakura, T. Terada, T. Katsura, and K.-I. Inui Characterization of the human peptide transporter PEPT1 promoter: Sp1 functions as a basal transcriptional regulator of human PEPT1 Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G471 - G477. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Adibi Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease Am J Physiol Gastrointest Liver Physiol, November 1, 2003; 285(5): G779 - G788. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Pan, T. Terada, M. Okuda, and K.-I. Inui Altered Diurnal Rhythm of Intestinal Peptide Transporter by Fasting and Its Effects on the Pharmacokinetics of Ceftibuten J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 626 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Daniel and I. Rubio-Aliaga An update on renal peptide transporters Am J Physiol Renal Physiol, May 1, 2003; 284(5): F885 - F892. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matysiak-Budnik, M. Heyman, C. Candalh, D. Lethuaire, and F. Megraud In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori J. Antimicrob. Chemother., December 1, 2002; 50(6): 865 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ashida, T. Katsura, H. Motohashi, H. Saito, and K.-I. Inui Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells Am J Physiol Gastrointest Liver Physiol, April 1, 2002; 282(4): G617 - G623. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||